Thu, March 10, 2022

Kemp Dolliver Initiated (VRCA) at Strong Buy and Held Target at $20 on, Mar 10th, 2022

Kemp Dolliver of Brookline Capital, Initiated "Verrica Pharmaceuticals Inc." (VRCA) at Strong Buy and Held Target at $20 on, Mar 10th, 2022.

Kemp has made no other calls on VRCA in the last 4 months.



There is 1 other peer that has a rating on VRCA. Out of the 1 peers that are also analyzing VRCA, 0 agree with Kemp's Rating of Hold.



This is the rating of the analyst that currently disagrees with Kemp


  • Serge Belanger of "Needham" Maintained at Strong Buy with Decreased Target to $18 on, Thursday, March 3rd, 2022